Tin tức & Cập nhật

Treatment with the combination of regorafenib, nivolumab, and short-course radiotherapy (SCRT) in the neoadjuvant setting has induced response in stage II-III rectal adenocarcinoma in the phase II REGINA trial, meeting the predefined statistical criteria.

First-line treatment with nivolumab (NIVO) in combination with ipilimumab (IPI) results in better health-related quality of life (HRQOL) and fewer symptoms, when compared with chemotherapy, in patients with centrally confirmed microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (CRC), as shown in the CheckMate 8HW study presented at ESMO GI 2024.

The two-drug regimen dolutegravir plus lamivudine (DTG/3TC) is as good as 3- or 4-drug antiretroviral therapy (ART) regimens at keeping viral load suppressed while helping avoid hepatitis B virus (HBV) reactivation in people living with HIV-1 who have past exposure to HBV but no immunity, according to a post hoc analysis of five phase 3/3b studies.